Position in JNJ
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$11,314,616
+$431,904 QoQ
Shares Held
44,551
+0.1% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.40%
of 13F equity value
Holder Rank
#1,038
of 4,664 holders
Holding Since
Mar 2024
10 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in JNJ Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026BNP PARIBAS holds $145,518,414 across 9 Drug Manufacturers - General names. JNJ ranks #6 (7.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
38,251 | $45,879,399 | |
| 2 | ABBV |
AbbVie Inc.
|
79,596 | $20,029,536 | |
| 3 | PFE |
Pfizer Inc
|
810,791 | $19,523,846 | |
| 4 | AMGN |
Amgen Inc
|
44,979 | $16,287,794 | |
| 5 | GILD |
Gilead Sciences, Inc.
|
118,671 | $14,992,893 | |
| 6 | JNJ |
Johnson & Johnson
This page
|
44,551 | $11,314,616 | |
| 7 | MRK |
Merck & Co., Inc.
|
74,751 | $9,605,503 | |
| 8 | BMY |
Bristol Myers Squibb Co
|
120,493 | $6,942,806 |
All Filings in JNJ
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $11,314,616 | 44,551 | Shares | Defined | 2026-08-13 | |
| 2026-03-31 | $10,882,712 | 44,521 | Shares | Defined | 2026-05-12 | |
| 2025-12-31 | $8,724,183 | 42,156 | Shares | Defined | 2026-02-10 | |
| 2025-09-30 | $2,942,614 | 15,870 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $2,246,188 | 14,705 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $2,495,061 | 15,045 | Shares | Defined | 2025-05-15 | |
| 2024-12-31 | $2,931,157 | 20,268 | Shares | Defined | 2025-02-14 | |
| 2024-09-30 | $2,606,896 | 16,086 | Shares | Defined | 2024-11-13 | |
| 2024-06-30 | $2,379,483 | 16,280 | Shares | Defined | 2024-08-13 | |
| 2024-03-31 | $3,549,940 | 22,441 | Shares | Defined | 2024-05-02 | |
| No filing history on record for this holder in this stock. | ||||||